Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hippocampus | 12 | 2021 | 471 | 1.970 |
Why?
|
| Neuronal Plasticity | 4 | 2019 | 274 | 1.310 |
Why?
|
| Receptor, Insulin | 7 | 2015 | 71 | 1.260 |
Why?
|
| Insulin Resistance | 5 | 2019 | 241 | 1.170 |
Why?
|
| Leptin | 4 | 2017 | 80 | 1.000 |
Why?
|
| Food Deprivation | 2 | 2014 | 22 | 0.870 |
Why?
|
| Physical Conditioning, Animal | 1 | 2022 | 34 | 0.830 |
Why?
|
| Obesity | 5 | 2021 | 1074 | 0.810 |
Why?
|
| Hypothalamus | 3 | 2014 | 78 | 0.600 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2015 | 2083 | 0.540 |
Why?
|
| Spatial Learning | 1 | 2015 | 12 | 0.540 |
Why?
|
| Anhedonia | 1 | 2014 | 15 | 0.490 |
Why?
|
| Rats | 17 | 2021 | 5300 | 0.480 |
Why?
|
| Down-Regulation | 2 | 2011 | 447 | 0.440 |
Why?
|
| Thiazepines | 3 | 2012 | 14 | 0.430 |
Why?
|
| Amygdala | 3 | 2012 | 159 | 0.430 |
Why?
|
| Stress, Psychological | 5 | 2012 | 824 | 0.390 |
Why?
|
| Animals | 22 | 2022 | 20877 | 0.390 |
Why?
|
| Conditioning, Classical | 1 | 2011 | 57 | 0.380 |
Why?
|
| Long-Term Potentiation | 1 | 2010 | 53 | 0.380 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2007 | 124 | 0.270 |
Why?
|
| Body Weight | 3 | 2014 | 554 | 0.270 |
Why?
|
| Gene Expression Regulation | 4 | 2012 | 1293 | 0.270 |
Why?
|
| Neurons | 1 | 2011 | 881 | 0.260 |
Why?
|
| Phosphorylation | 3 | 2015 | 1199 | 0.240 |
Why?
|
| Receptors, AMPA | 3 | 2015 | 99 | 0.240 |
Why?
|
| Depression | 1 | 2011 | 942 | 0.240 |
Why?
|
| Biological Evolution | 1 | 2022 | 86 | 0.200 |
Why?
|
| Citalopram | 1 | 2021 | 29 | 0.200 |
Why?
|
| Diet, High-Fat | 1 | 2021 | 81 | 0.190 |
Why?
|
| Corticosterone | 3 | 2010 | 51 | 0.190 |
Why?
|
| Adiposity | 2 | 2011 | 88 | 0.190 |
Why?
|
| Insulin | 4 | 2011 | 617 | 0.170 |
Why?
|
| Models, Biological | 2 | 2022 | 981 | 0.170 |
Why?
|
| Phenotype | 1 | 2022 | 946 | 0.170 |
Why?
|
| Male | 14 | 2015 | 37281 | 0.170 |
Why?
|
| Computer Simulation | 1 | 2022 | 705 | 0.160 |
Why?
|
| Disease Models, Animal | 5 | 2012 | 2550 | 0.150 |
Why?
|
| Glutamic Acid | 2 | 2012 | 332 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 290 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2019 | 1085 | 0.140 |
Why?
|
| Eating | 2 | 2014 | 119 | 0.130 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2012 | 45 | 0.130 |
Why?
|
| Autoradiography | 3 | 2010 | 94 | 0.130 |
Why?
|
| Stress, Physiological | 2 | 2008 | 215 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2019 | 563 | 0.120 |
Why?
|
| Analysis of Variance | 3 | 2012 | 1039 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 180 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 266 | 0.110 |
Why?
|
| Ventromedial Hypothalamic Nucleus | 1 | 2011 | 1 | 0.100 |
Why?
|
| Ideal Body Weight | 1 | 2011 | 4 | 0.100 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 36 | 0.100 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2011 | 16 | 0.100 |
Why?
|
| Freezing Reaction, Cataleptic | 1 | 2011 | 10 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2017 | 659 | 0.100 |
Why?
|
| Electroshock | 1 | 2011 | 36 | 0.100 |
Why?
|
| Pancreatic Diseases | 1 | 2011 | 66 | 0.100 |
Why?
|
| Food Preferences | 1 | 2011 | 46 | 0.100 |
Why?
|
| Swimming | 1 | 2011 | 38 | 0.100 |
Why?
|
| RNA, Antisense | 1 | 2010 | 25 | 0.100 |
Why?
|
| Islets of Langerhans | 1 | 2011 | 87 | 0.100 |
Why?
|
| Maze Learning | 1 | 2011 | 138 | 0.100 |
Why?
|
| Triglycerides | 1 | 2011 | 184 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2011 | 114 | 0.100 |
Why?
|
| Serine | 1 | 2010 | 99 | 0.090 |
Why?
|
| Genetic Vectors | 1 | 2011 | 311 | 0.090 |
Why?
|
| Area Under Curve | 1 | 2010 | 238 | 0.090 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2007 | 50 | 0.090 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 765 | 0.090 |
Why?
|
| Cytokines | 1 | 2014 | 866 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 507 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2012 | 617 | 0.080 |
Why?
|
| Synaptophysin | 2 | 2004 | 16 | 0.080 |
Why?
|
| Appetite | 1 | 2007 | 16 | 0.080 |
Why?
|
| Furosemide | 2 | 2007 | 45 | 0.080 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2007 | 34 | 0.080 |
Why?
|
| Limbic System | 2 | 2008 | 106 | 0.070 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2007 | 39 | 0.070 |
Why?
|
| Receptors, Opioid | 1 | 2007 | 60 | 0.070 |
Why?
|
| Restraint, Physical | 1 | 2007 | 59 | 0.070 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2006 | 26 | 0.070 |
Why?
|
| Depressive Disorder | 2 | 2008 | 621 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 216 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2008 | 342 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2006 | 291 | 0.060 |
Why?
|
| Memory Disorders | 1 | 2005 | 111 | 0.060 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 54 | 0.060 |
Why?
|
| Amphetamine | 1 | 2004 | 77 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 529 | 0.060 |
Why?
|
| Desoxycorticosterone | 1 | 2003 | 41 | 0.060 |
Why?
|
| Sodium, Dietary | 1 | 2003 | 31 | 0.060 |
Why?
|
| Dynorphins | 1 | 2003 | 69 | 0.060 |
Why?
|
| Aging | 1 | 2008 | 911 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2004 | 195 | 0.050 |
Why?
|
| Naltrexone | 1 | 2003 | 195 | 0.050 |
Why?
|
| Cognition | 1 | 2005 | 512 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 370 | 0.050 |
Why?
|
| RNA, Messenger | 4 | 2006 | 1663 | 0.050 |
Why?
|
| Microdialysis | 2 | 2012 | 147 | 0.050 |
Why?
|
| Humans | 5 | 2021 | 68525 | 0.050 |
Why?
|
| Brain | 1 | 2008 | 2175 | 0.040 |
Why?
|
| Time Factors | 3 | 2012 | 4655 | 0.030 |
Why?
|
| Glucose | 2 | 2008 | 307 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2011 | 631 | 0.030 |
Why?
|
| Dopamine Antagonists | 2 | 2007 | 65 | 0.030 |
Why?
|
| Protein Transport | 2 | 2007 | 280 | 0.030 |
Why?
|
| Cell Membrane | 2 | 2007 | 523 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2004 | 201 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2017 | 2688 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 132 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2005 | 954 | 0.030 |
Why?
|
| Glucose Clamp Technique | 1 | 2011 | 24 | 0.030 |
Why?
|
| Nucleus Accumbens | 2 | 2007 | 417 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2008 | 1329 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2011 | 167 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 196 | 0.020 |
Why?
|
| Weight Gain | 1 | 2011 | 135 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 266 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 434 | 0.020 |
Why?
|
| tau Proteins | 1 | 2008 | 61 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2008 | 102 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2008 | 150 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 2008 | 138 | 0.020 |
Why?
|
| Sodium Channel Blockers | 1 | 2007 | 23 | 0.020 |
Why?
|
| Fluoxetine | 1 | 2007 | 40 | 0.020 |
Why?
|
| Extracellular Fluid | 1 | 2007 | 29 | 0.020 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2007 | 53 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2006 | 17 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2007 | 200 | 0.020 |
Why?
|
| Diuretics | 1 | 2007 | 96 | 0.020 |
Why?
|
| Ventral Tegmental Area | 1 | 2007 | 74 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2008 | 158 | 0.020 |
Why?
|
| Axons | 1 | 2007 | 139 | 0.020 |
Why?
|
| Rats, Zucker | 1 | 2005 | 10 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2006 | 246 | 0.020 |
Why?
|
| Reinforcement Schedule | 1 | 2005 | 59 | 0.020 |
Why?
|
| Acute Disease | 1 | 2007 | 658 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2007 | 224 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2005 | 85 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2006 | 222 | 0.020 |
Why?
|
| Anxiety | 1 | 2008 | 422 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2007 | 682 | 0.020 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2004 | 6 | 0.020 |
Why?
|
| Microsomes | 1 | 2004 | 31 | 0.020 |
Why?
|
| Gene Expression | 1 | 2007 | 770 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 164 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2007 | 531 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2005 | 213 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2004 | 79 | 0.010 |
Why?
|
| Thirst | 1 | 2003 | 4 | 0.010 |
Why?
|
| Raclopride | 1 | 2003 | 15 | 0.010 |
Why?
|
| Diuresis | 1 | 2003 | 20 | 0.010 |
Why?
|
| Drinking | 1 | 2003 | 35 | 0.010 |
Why?
|
| Enkephalins | 1 | 2003 | 89 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2003 | 136 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 81 | 0.010 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2003 | 82 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2005 | 470 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 442 | 0.010 |
Why?
|
| Water | 1 | 2003 | 228 | 0.010 |
Why?
|
| Narcotic Antagonists | 1 | 2003 | 184 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 693 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1174 | 0.010 |
Why?
|
| Corpus Striatum | 1 | 2003 | 278 | 0.010 |
Why?
|
| Motor Activity | 1 | 2004 | 621 | 0.010 |
Why?
|
| Female | 1 | 2004 | 38015 | 0.000 |
Why?
|